GlassScriptPhysician profile
Michelle K Le
NPI 1346905171
$3,347.15
in general payments reported to CMS, 2019-2025
33 companies · $1,851 in 2025
The $1,851 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $195 · 2023: $106 · 2024: $1,195 · 2025: $1,851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,849 · Education: $303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.14 |
| Education | $302.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $507.84 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $501.89 | 2022-2025 | Rybrevant, Carvykti, Darzalex |
| Novartis Pharmaceuticals Corporation | $268.99 | 2024-2025 | |
| Pfizer INC. | $244.17 | 2024-2025 | |
| Daiichi Sankyo INC. | $238.32 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Sobi, INC | $226.46 | 2024-2025 | |
| Puma Biotechnology, INC. | $110.87 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.97 | 2024-2025 | Fruzaqla, Ninlaro |
| Lilly USA, LLC | $101.60 | 2025 | Verzenio, Jaypirca |
| Seagen INC. | $92.99 | 2025 | |
| Abbvie INC. | $86.49 | 2024-2025 | |
| Beone Medicines USA, INC. | $75.43 | 2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $68.27 | 2024 | |
| Eisai INC. | $64.24 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.29 | 2022-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $61.72 | 2024 | |
| Karyopharm Therapeutics INC. | $59.48 | 2025 | Xpovio |
| Celgene Corporation | $54.58 | 2025 | Reblozyl |
| Janssen Pharmaceuticals, INC | $47.86 | 2022 | |
| Glaxosmithkline, LLC. | $44.76 | 2024 | Jemperli, Zejula |
| Myriad Genetic Laboratories, INC. | $33.85 | 2024 | Myrisk |
| Amgen INC. | $32.72 | 2025 | |
| Incyte Corporation | $26.83 | 2025 | Jakafi |
| Emd Serono, INC. | $25.95 | 2024 | |
| Blueprint Medicines Corporation | $25.53 | 2025 | Ayvakit |
| Array Biopharma INC | $25.39 | 2024 | Tukysa, Braftovi, Mektovi |
| Genzyme Corporation | $24.96 | 2025 | |
| Genentech USA, INC. | $24.75 | 2025 | Polivy |
| Kite Pharma, INC. | $24.66 | 2025 | Yescarta |
| Rigel Pharmaceuticals, INC. | $23.43 | 2022 | |
| Coherus Oncology, INC. | $21.44 | 2025 | Loqtorzi |
| Pharmacosmos Therapeutics INC. | $18.66 | 2025 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $17.76 | 2025 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.